Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Mod Pathol. 2018 Jan 12;31(5):690–704. doi: 10.1038/modpathol.2017.182

FIGURE 3. Patient 8, Time course of laboratory and histopathologic features in a patient with simultaneously identified BCR-ABL1 and JAK2 V617F. Tyrosine kinase inhibitor therapy for BCR-ABL1 unmasks an essential thrombocythemia phenotype37.

FIGURE 3

A. Time course of BCR-ABL1 transcript levels (log scale), cytogenetic t(9;22) results (Cyto), JAK2 V617F status, treatment, peripheral blood counts, and bone marrow morphology. B. Bone marrow core biopsy at initial diagnosis (month 0) showing predominant features of chronic myeloid leukemia. Hypercellular (top), elevated M:E ratio (middle), small hypolobated megakaryocytes (bottom). C and D. Bone marrow core biopsy after tyrosine kinase inhibitor therapy (month 6 and month 13, respectively) showing predominant features of essential thrombocythemia. Normocellular (C) to mildly hypercellular (D), hyperlobated “staghorn” megakaryocytes with clustering (middle and bottom).